Mortality ‐ within 30 days · people with upper gastrointestinal bleeding prior to endoscopic diagnosis
Proton pump inhibitor treatment showed no clear difference in mortality ‐ within 30 days compared with H2RA, placebo or no treatment (low certainty).
1 finding from 1 review
Rebleeding · people with upper gastrointestinal bleeding prior to endoscopic diagnosis
Proton pump inhibitor treatment showed no clear difference in rebleeding ‐ within 30 days compared with H2RA, placebo or no treatment (low certainty).
1 finding from 1 review
Surgery ‐ within 30 days · people with upper gastrointestinal bleeding prior to endoscopic diagnosis
Proton pump inhibitor treatment showed no clear difference in surgery ‐ within 30 days compared with H2RA, placebo or no treatment (low certainty).
1 finding from 1 review
Proportion of participants with stigmata of recent haemorrhage at index endoscopy · people with upper gastrointestinal bleeding prior to endoscopic diagnosis
Proton pump inhibitor treatment showed no clear difference in proportion of participants with stigmata of recent haemorrhage at… compared with H2RA, placebo or no treatment (low certainty).
1 finding from 1 review
Endoscopic haemostatic treatment at index endoscopy · people with upper gastrointestinal bleeding prior to endoscopic diagnosis
Proton pump inhibitor treatment probably leads to lower endoscopic haemostatic treatment at index endoscopy compared with H2RA, placebo or no treatment (moderate certainty).
1 finding from 1 review
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical remission compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical improvement compared with beclometasone (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus may leads to higher clinical improvement compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical remission compared with ciclosporin (very low certainty).
1 finding from 1 review
Clinical improvement · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes clinical improvement compared with ciclosporin (very low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in clinical remission compared with beclometasone (low certainty).
1 finding from 1 review
Post‐ERCP pancreatitis · Patients undergoing diagnostic or therapeutic ERCP
Guidewire‐assisted cannulation probably leads to lower post‐ERCP pancreatitis (PEP) compared with contrast‐assisted cannulation (moderate certainty).
1 finding from 1 review
Primary cannulation success · Patients undergoing diagnostic or therapeutic ERCP
Guidewire‐assisted cannulation may leads to higher primary cannulation success compared with contrast‐assisted cannulation (low certainty).
1 finding from 1 review
Overall success of cannulation · Patients undergoing diagnostic or therapeutic ERCP
Guidewire‐assisted cannulation showed no clear difference in overall cannulation success compared with contrast‐assisted cannulation (moderate certainty).
1 finding from 1 review